What's The Outlook From Life Science Operations For 2022 — And Beyond?
By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
In 2015, when we published our first manufacturing outlook article, biologics accounted for less than 5% of total sales. Perhaps that’s why the article only included “Pharma Manufacturing” in its title. What a difference six years make, as biologics in at least four countries now constitute more than 30% of total pharmaceutical sales. But, with the average daily dose of a biologic costing roughly 22 times more than a small molecule, it seems that leaders in biopharmaceutical manufacturing have never faced a greater challenge. Here’s what 12 biopharma manufacturing execs have to say as they look to 2022 and beyond.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.